Jennison Associates LLC Buys New Position in Bio-Techne Corp $TECH

Posted by Stanley Muller on Jul 22nd, 2026

Jennison Associates LLC bought a new stake in Bio-Techne Corp (NASDAQ:TECH – Free Report) during the 1st quarter, Holdings Channel.com reports. The firm bought 119,213 shares of the biotechnology company’s stock, valued at approximately $6,230,000.

A number of other large investors have also recently bought and sold shares of TECH. Danske Bank A S acquired a new stake in shares of Bio-Techne in the fourth quarter valued at approximately $29,000. eCIO Inc. acquired a new position in Bio-Techne during the fourth quarter worth $30,000. Measured Wealth Private Client Group LLC acquired a new position in Bio-Techne during the third quarter worth $32,000. iSAM Funds UK Ltd bought a new position in Bio-Techne in the third quarter valued at $33,000. Finally, EverSource Wealth Advisors LLC grew its position in Bio-Techne by 506.3% in the second quarter. EverSource Wealth Advisors LLC now owns 673 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 562 shares in the last quarter. Institutional investors and hedge funds own 98.95% of the company’s stock.

Bio-Techne Stock Down 0.0%

Bio-Techne stock opened at $71.63 on Wednesday. The stock has a market cap of $11.22 billion, a P/E ratio of 103.81, a P/E/G ratio of 8.53 and a beta of 1.29. The company has a quick ratio of 3.18, a current ratio of 4.49 and a debt-to-equity ratio of 0.10. Bio-Techne Corp has a twelve month low of $43.19 and a twelve month high of $72.16. The company’s 50-day moving average price is $58.84 and its two-hundred day moving average price is $58.56.

Bio-Techne (NASDAQ:TECH – Get Free Report) last issued its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $0.53 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.55 by ($0.02). Bio-Techne had a return on equity of 13.57% and a net margin of 9.05%.The firm had revenue of $311.42 million for the quarter, compared to the consensus estimate of $316.11 million. During the same quarter in the prior year, the firm earned $0.56 EPS. The company’s revenue was down 1.5% on a year-over-year basis. As a group, analysts expect that Bio-Techne Corp will post 1.65 EPS for the current year.

Bio-Techne Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, May 29th. Shareholders of record on Monday, May 18th were issued a $0.08 dividend. This represents a $0.32 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date of this dividend was Monday, May 18th. Bio-Techne’s dividend payout ratio is currently 46.38%.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on TECH. Weiss Ratings upgraded shares of Bio-Techne from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, May 7th. Robert W. Baird lifted their target price on Bio-Techne from $49.00 to $73.00 and gave the company a “neutral” rating in a research report on Friday, June 26th. Wells Fargo & Company dropped their target price on Bio-Techne from $76.00 to $62.00 and set an “overweight” rating on the stock in a report on Thursday, May 7th. Zacks Research downgraded Bio-Techne from a “hold” rating to a “strong sell” rating in a research note on Monday, June 8th. Finally, Stephens set a $73.00 price target on Bio-Techne and gave the stock an “equal weight” rating in a research report on Friday, June 26th. Three analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $68.08.

Get Our Latest Analysis on Bio-Techne

About Bio-Techne

(Free Report)

Bio-Techne Corporation (NASDAQ:TECH) is a global life sciences company that develops, manufactures and sells high-quality reagents, instruments and services for the research, diagnostic and bioprocessing markets. Its core product offerings include recombinant proteins, antibodies, immunoassays, nucleic acid probes and kits, single-cell analysis solutions and automated protein analysis systems. Flagship brands such as R&D Systems, Novus Biologicals, ProteinSimple and Advanced Cell Diagnostics provide researchers and clinicians with reliable tools for cell biology, immunology, proteomics and genomics applications.

Headquartered in Minneapolis, Minnesota, Bio-Techne serves customers across North America, Europe and the Asia-Pacific region through a combination of direct sales, distributors and strategic partnerships.